Adverse events related to bevacizumab and the management principles in non-small cell lung cancer.
10.3779/j.issn.1009-3419.2010.06.001
- Author:
Gang CHENG
;
Li ZHANG
- Publication Type:Editorial
- MeSH:
Angiogenesis Inhibitors;
adverse effects;
Antibodies, Monoclonal;
adverse effects;
Antibodies, Monoclonal, Humanized;
Bevacizumab;
Carcinoma, Non-Small-Cell Lung;
drug therapy;
Hemorrhage;
chemically induced;
Humans;
Hypertension;
chemically induced;
Lung Neoplasms;
drug therapy;
Proteinuria;
chemically induced;
Thromboembolism;
chemically induced
- From:
Chinese Journal of Lung Cancer
2010;13(6):563-567
- CountryChina
- Language:Chinese
